NTLA

Four biotech companies with advanced drug pipelines present potential investment opportunities as their experimental treatments progress through late-stage development and regulatory review. BridgeBio Pharma has three drug candidates under FDA review with decisions expected through May 2027.

Intellia Therapeutics' gene-editing therapy lonvo-z showed 87% reduction in hereditary angioedema attacks. Biogen expects pivotal study results through 2027, while Viking Therapeutics advances obesity treatments in phase III trials. Success depends on regulatory approvals, clinical efficacy, and competitive market positioning.

Intellia Therapeutics shares rallied 7.6% following FDA acceptance of its CRISPR-based HAE treatment under Priority Review with a March 2027 decision date, and a $400 million debt facility secured in September. However, the stock carries a Hold rating as earnings estimate revisions remain unchanged, and the company faces declining revenues and quarterly losses.